Results 161 to 170 of about 4,565 (213)

Population pharmacokinetics of meropenem-vaborbactam in acutely ill hospitalized patients with various degrees of renal dysfunction including continuous renal replacement therapy. [PDF]

Antimicrob Agents Chemother
Reed G, Valadez A, Smith BJ, McCreary EK, Kline EG, Neely MN, Squires KM, Shields RK, Rhodes NJ.   +8 more
europepmc   +1 more source

Imipenem/Relebactam Plus Aztreonam: First Reported Use in MDR <i>Klebsiella pneumoniae</i> Sternal Infection Complicated by Bacteremia. [PDF]

Antibiotics (Basel)
Pipitò L, Rubino R, Immordino R, Bono E, Fasciana T, Bonura C, Giammanco GM, Argano V, Cascio A.   +8 more
europepmc   +1 more source

UK Antimicrobial Registry: Virtual Registry-an innovative surveillance approach for monitoring the real-world use and effectiveness of newly licensed antimicrobials in Scotland. [PDF]

JAC Antimicrob Resist
Goswami C, Turgal E, Mueller T, Bennie M, Parr R, Jones GT, Seaton RA, Jenkins D, Baltas I, Sneddon J, Sandoe JAT, Garraghan F, Brown NM, Macfarlane GJ, Kurdi A.   +14 more
europepmc   +1 more source

Meropenem/vaborbactam activity against carbapenem-resistant Klebsiella pneumoniae from catheter-related bloodstream infections. [PDF]

Front Cell Infect Microbiol
Sivori F, Francalancia M, Truglio M, Cavallo I, Pronesti C, Fabrizio G, Celesti I, Cazzani A, Furzi L, Pimpinelli F, Di Domenico EG.   +10 more
europepmc   +1 more source

Genomic and molecular characterisation of a Klebsiella pneumoniae clinical isolate resistant to meropenem-vaborbactam, imipenem-relebactam, and ceftazidime-avibactam

Wan Y, Wong JLC, Sanchez-Garrido J, Low WW, Turton JF, Morecchiato F, Baccani I, Dodgson K, Rossolini GM, Woodford N, Frankel G, Jauneikaite E, Meunier D, Hopkins KL.   +13 more
europepmc   +1 more source